It’s time to reduce API imports: Granules India

Hyderabad: As India’s pharmaceutical industry cements its position as the world’s third-largest by volume, the upcoming Union Budget presents a crucial opportunity to accelerate our trans-formation into a global healthcare leader. With our industry projected to reach $120-130 billion by 2030, we must address the critical challenge of API dependency, said Priyanka Chigurupati, Executive Director, Granules India

“Currently, 60-65 per cent of our API requirements are met through imports, highlighting the ur-gent need to expand the Production Linked Incentive scheme beyond its current Rs15,000 crore outlay. This expansion would be vital in building a more resilient and self-reliant pharmaceutical ecosystem,” Priyanka Chigurupati explained.

The path to global leadership must be paved with sustainable practices. As we scale our opera-tions, integrating green manufacturing technologies isn’t just an environmental choice – it’s a stra-tegic imperative that will define our industry’s future competitiveness. “By incentivizing eco-friendly production methods, we can position India as a pioneer in sustain-able pharmaceutical manufacturing, while meeting our environmental commitments,” remarked Chigurupati.